Advertisement

Effective immediately, the FDA transfers review of certain live-cell wound care therapies from the Center for Devices & Radiological Health to the Center for Biologics Evaluation & Research.

FDA transfers certain wound care review responsiblities within agency

The FDA is shifting some of its wound care review responsibilities away from the Center for Devices & Radiological Health, handing them instead to the Center for Biologics Evaluation & Research.

Some of the products transfered include the Apligraf diabetic foot and venous leg ulcer treatment from Organogenesis and the Dermagraft venous leg ulcer skin substitute by Shire (NSDQ:SHPGY) subsidiary Advanced BioHealing, according to a notice in the Federal Register.

Advertisement
Advertisement